Organisation paid for research Program year 2025 Source: CMS Open Payments

Central Texas Neurology

Neither a doctor nor a teaching hospital

Research payments

$320,251

55 payments

Through program year 2025, Central Texas Neurology is reported as receiving $320,251 in research payments, across 55 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $13,962 2
2024 Research $90,244 1
2022 Research $97,032 16
2020 Research $26,965 8
2019 Research $92,049 28

Breakdown

Who paid Research payments · program years 2019–2025
  1. Ucb SA $100,162 2 payments
  2. Adamas Pharmaceuticals, Inc. $99,030 33 payments
  3. Jazz Pharmaceuticals Inc. $26,534 4 payments
  4. F. Hoffmann-La Roche AG $24,801 2 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $22,687 5 payments
  6. Roche Products Limited $19,859 3 payments
  7. H. Lundbeck A S $10,995 1 payment
  8. Genentech, Inc. $7,195 3 payments
  9. Celgene Corporation $4,989 1 payment
  10. Teva Pharmaceuticals USA, Inc. $4,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter Phase 2, Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Ucb0022 in Study Participants With Advanced Parkinson's Disease $90,244 1 payment
  2. A 3-Arm Multicenter Double-Blind Placebo-Controlled Randomized Study to Assess the Efficacy and Safety of Ads-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment $60,749 20 payments
  3. A Multicenter Open-Label Safety and Efficacy Study of Ads-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment $38,281 13 payments
  4. Satralizumab Open Label Treatment Study in Patients With Nmosd $34,660 4 payments
  5. A Double-Blind Randomized Placebo-Controlled Parallel-Group Trial of the Efficacy and Safety of Nabiximols Oromucosal Spray As Add-On Therapy in Patients With Spasticity Due to Multiple Sclerosis $22,490 3 payments
  6. A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Tak-071 in Parkinson Disease Patients With Cognitive Impairment and An Elevated Risk of Falls $14,937 2 payments
  7. Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension RESTORE $10,995 1 payment
  8. Patient Experience Interviews to Inform A Digital Assessment of Huntingtons Disease $10,000 1 payment
  9. A Multicenter Phase 2, Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Ucb0022 in Study Participants With Advanced Parkinsons Disease $9,918 1 payment
  10. A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Tak-079 in Patients With Generalized Myasthenia Gravis $7,750 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record